The company will use the proceeds to support development of its liquid biopsy tests and the launch of its lung cancer test in the second half of this year.
The company previously said that it planned to publicly offer up to $10 million in stocks and warrants. It has not priced the offering yet.
The company said in an SEC document that it will offer about 6.3 million shares of its common stock. Some purchasers would also be able to buy prefunded warrants.
The funds will help the company prepare for CLIA certification of its lab ahead of the planned launch of its lung cancer test.
Certain investors have agreed to buy 375,000 shares of Interpaces common stock at $6.75 per share, and 255,000 prefunded warrants to purchase common stock at $6.74 per share.
The Rutherford, NJ-based cancer molecular diagnostics firm will use the proceeds for general corporate purposes.
The Salt Lake City-based company said it would use the $18.4 million in expected gross aggregate proceeds for product pipeline development and customer growth.
The molecular diagnostics firm has retained Roth Capital Partners as financial advisor to assist in restructuring Series C Warrants issued in March.
The firm closed its existing debt facility with Silicon Valley Bank and Oxford Finance and plans to use the funds for general corporate purposes and working capital.
The offering raised net proceeds of $6.2 million, which will be used for working capital and general corporate purposes, the firm said.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.